3rd International
Cancer Study & Therapy Conference

May 2-4, 2018 | Rome, Italy

Collaborated with WAMS, The World Academy of Medical Sciences

Program Schedule

  • Keynote Speaker

    Time:
    10:45-11:15

    Title

    Title: The Pivotal OCA/OTA/OCATA Status in Microenvironment and its Cruciality in Oncogenesis

    M. M. Karindas
    Clinical and Molecular Oncologist Academy Professor of Oncology, President, The World Academy of Medical Sciences, Netherlands
    Biography
    χ

    Biography

    M. M. Karindas
    Clinical and Molecular Oncologist Academy Professor of Oncology, President, The World Academy of Medical Sciences, Netherlands

    Dr. M. M. Karindas is the President of the WAMS, the World Academy of Medical Sciences, where he has been serving as its leader for more than two decades now. Having extensive experience as a research scientist in Clinical and Molecular Oncology, he is the holder of landmark theories including the "Multicellular Origin of Cancer" and "Oncogenetic Evolution" as well as the OCA/OTA/OCATA and ECE research studies. He is the creator and writer of the KGS, the “Karindas Grading System”, the all-encompassing universal paradigm of tumor grading and a new integral method of clinical management in oncology. He is also the writer and declarant of the phenomenal "International Declaration of Oncogenesis" whose Part III (OCA/OTA/OCATA in Oncogenesis) will be presented by him at ICST-2018 in Rome. Having his main research interests in "Oncogenesis", "Metastasis", "Cancer Stem Cells", "Tumor Cell Biology", "Molecular Oncopathology", "Cell Signaling", "Signal Transduction", "Extracellular Matrix" and the "Origin and Evolution of Cancer ", he is currently busy working on the creation and establishment of a new medical algorithmic system which will universally be used in oncology as well as other fields of medicine.



    Abstract
    χ

    Abstract

    M. M. Karindas
    Clinical and Molecular Oncologist Academy Professor of Oncology, President, The World Academy of Medical Sciences, Netherlands

    My speech will take about three hours in rather a Lecture & Discussion format and its duration may be divided between the three days of the Conference. Apart from the title, there'll be no display of details/abstract on the conference website until the conference day just to protect its breakthrough exclusive elements in terms of scientific intellectual confidentiality.

    Keynote Speaker

    Time:
    10:00-10:30

    Title

    Title: Liquid Biopsy Monitoring of Circulating Cell-Free Tumor DNA and Identification of Cancer Gene Variations for Precision Diagnostics

    Michael J. Powell
    DiaCarta, Inc., USA
    Biography
    χ

    Biography

    Michael J. Powell
    DiaCarta, Inc., USA

    Mike is currently Chief Scientific Officer at DiaCarta, Inc. where he manages the company’s scientific and strategic direction in molecular diagnostics for oncology and infectious disease personalized diagnostics markets, most notably the development of branched DNA (bDNA) signal amplification and a novel somatic gene mutation Real-Time PCR based assay technology called QClampTM for applications in the diagnosis of cancer and infectious diseases and the rapid detection of cancer 'driver' and drug resistance genetic variations. Mike was previously a Founder of Odyssey Thera Inc., a privately held company that commercialized a proprietary fluorescent live cell-based assay and diagnostic imaging technology for the application in target validation and drug discovery. Mike was the Director of New Technology at Roche Diagnostics (Roche acquired Boehringer Mannheim Corporation in May, 1997 for $11B). Prior to the acquisition by Roche he was Director of New Technology at Boehringer Mannheim. He was also the Director of New Technology at Microgenics Corporation, in Concord, California. He was pioneer and lead scientist and inventor of the electrochemiluminescence (ECL) assay technology and also developed catalytic antibodies at IGEN, Inc. The ECL technology is the basis of Roche Diagnostics automated ‘in-vitro’ diagnostics immunoassay platform: ‘ElecSys’. Mike has held several other R & D senior management positions at Integrated Genetics Inc., Medisense and Celltech PLC, in the UK. Mike has published many research papers in leading scientific journals and holds over 30 patents and patent-pending applications. He received his Ph.D. in medicinal organic chemistry from Loughborough University, Loughborough, UK and Ph.D. from University of Nottingham, Nottingham, UK.



    Abstract
    χ

    Abstract

    Michael J. Powell
    DiaCarta, Inc., USA

    Current clinically available molecular tests for detection of nucleic acid variations especially those performed on circulating cell-free nucleic acids present in biological fluids such as patient’s blood plasma have limited sensitivity. In order to achieve high sensitivity for the detection of only a few target molecules (mutant alleles) present in a vast excess of non-target molecules (wild-type alleles) sophisticated methodologies that require expensive instrumentation, highly skilled operators and in some cases intensive computational bioinformatics methods such as digital-droplet PCR (ddPCR), BEAMing PCR and next generation deep sequencing (NGS) are being employed in large clinical research centers. The limited availability, high cost and long analysis times of these methods prompted us to develop a new technology that can be performed globally by existing pathology personnel with instrumentation that is already present in every hospital pathology laboratory. At the heart of this innovative technology are new molecular nucleic acid analogs: xenonucleic acids (XNA) that possess all the natural bases that occur in DNA appended to a novel chemical backbone that imbibes these oligomeric nucleic acid binding molecules with exquisite specificity and extremely avid binding affinity for complementary target sequences. Any variation in the sequence that the XNA binds to creates a differential thermodynamic free energy of binding anomaly that has been exploited to develop target amplification based real-time qPCR and extremely high sensitivity NGS and bead-based hybridization capture assays that can detect as little as 2 copies of variant templates in a large excess of wild-type templates in DNA obtained from tissue biopsies or plasma circulating cell free DNA (cfDNA). Commercial CE/IVD Certified Products that have been developed and validated include QClampTM gene specific real-time qPCR based tests, a new colorectal cancer detection test called ColoScapeTM a high sensitivity amplicon based target NGS platform called OptiSeqTM and a multiplex target amplicon hybridization capture technology for monitoring drug sensitizing and resistance mutations in cancer patients. This presentation will discuss this new ground-breaking technology and the precision diagnostics and targeted therapy opportunities that it affords.

    Keynote Speaker

    Time:
    11:15-11:45

    Title

    Title: The Difficulty to get Psycho-Social Cancer Care Reimbursed: Cancer patients’ Use and Evaluation of Psychosocial Care after Drastic Changes in Dutch Health Care Policy

    Adriaan Visser
    Pro-health.org, The Netherlands
    Biography
    χ

    Biography

    Adriaan Visser
    Pro-health.org, The Netherlands

    Adriaan Visser (1941), PhD, studied social psychology at the Free University, Amsterdam (NL). The published thesis (1984) was on the methodology of the measurement of patient satisfaction. Worked the rest of his life mostly as health psychologist, engaged in education of university and high school students (psychology, medical, nursing), research in health care, implementation of health care changes, writing, and editing. Nearly 100 grants have been awarded and a lot articles published on patient education, organization of health care, dental care, diabetes, fibromialgie, psychosocial cancer care, breast cancer, prostate cancer, palliative care, aging, family planning, psycho-neuroimmunology (PNI), depression, mindfulness, complementary medicine, and spirituality.



    Abstract
    χ

    Abstract

    Adriaan Visser
    Pro-health.org, The Netherlands

    Introduction: The Dutch health care insurance companies and the governmentally national health care legislation did restrict the offer of counseling for cancer patients and raised as well the fees for the counseling. The conditions concerning the financial cost for the patients became higher for less counseling in 2012-2015. These changes were often not well communicated to the therapeutical centres and their clients. In a study about the perceived and communicated effects of these changes were explored concerning the inflow of clients and their treatment evaluation. Method: The data was based on the yearly answered questionnaires at a big cancer centre, filled in after finishing the therapy by the clients. For this purpose, two groups of clients were formatted based on the occurring health insurance and legislation changes: clients receiving psycho-oncological care and filling in questionnaires in 2012/2013 (N=334) and clients from 2014/2015 (N=360). Analysing of the differences between both groups concerning inflow and evaluation, the differences in background characteristics were taken in account by using multivariate tests. Results: The results show that in 2014/2015 in comparison with 2012/2013 the clients were more often women, were more often a relative, were older, were longer diagnosed with cancer, and had more often received for them an unknown cancer prognosis. Also differences in the evaluation of the care were found on two treatment aspects. Clients in 2014/2015 were more complaining about the information provided about the therapy, their active participation by choosing a therapy, and about the counselors itself, e.g. their trustworthiness. Almost identical results were found for the three most commonly followed therapies separately: individual counseling, cognitive behavioural therapy, and art therapy. Discussion: The results indicate that the insufficient communication about the changes in the health care insurance as well as the national legislation of care conditions did harm the psychosocial counseling of cancer patients. The psycho-oncological care became less easily accessible and more negatively evaluated for some groups of clients. These effects might be caused by the changes in health insurance and legislation. Restrictions about the design, the subjective data, changes of therapists, and illness states of the clients will be discussed.

    Keynote Speaker

    Time:
    11:45-12:15

    Title

    Title: Targeted Radionuclide Oncology Therapy

    Gregory Wiseman
    Mayo Clinic, USA
    Biography
    χ

    Biography

    Gregory Wiseman
    Mayo Clinic, USA



    Abstract
    χ

    Abstract

    Gregory Wiseman
    Mayo Clinic, USA

    Malignant tumors have been treated with targeted radionuclides beginning with the treatment of thyroid cancers. More recently targeted radionuclides have been used to treat bone metastasis, lymphoma, hepatocellular carcinoma and neuroendocrine tumors (NETs). Many other treatment agents are under development for multiple types of cancer. Radioiodine treatment of thyroid cancer with iodine-131 targets the treatment to the tumor by using the tumor cell iodine symporter to deliver the therapy directly into the tumor cells. New targeted radionuclide treatment agents have used chemical binding, antibody binding, glass or resin embolization beads, or peptide receptor binding to selectively deliver the cytotoxic treatment to the cancer cells. Each of the target treatments agents uses a unique tumor specific localization method with a cytotoxic radionuclide. The radionuclides used are selected on the basis of the chemical binding, physical half-life, and path length of the therapeutic emission. Targeted radiation for cancer therapy allows the radiation doses to the tumor cells to be significantly higher due to lower radiation absorbed to the normal cells. As our knowledge of cancer cells increases we will be better able to more specifically deliver cytotoxic molecules including radionuclides to kill tumor cells and further improve cancer therapy.

    Sessions:
    Cancer Genetics and Biomarkers & Causes, Prevention and Treatment for different types of Cancers

    Time:
    12:15-12:40

    Title: The Potential Role of miR-126 as a Prognostic Biomarker in Renal Cell Carcinoma

    Jessica Carlsson
    Orebro University, Sweden

    Biography
    χ

    Biography

    Jessica Carlsson
    Orebro University, Sweden

    Jessica Carlsson is a researcher working in the Department of Urology at Orebro University Hospital in Sweden. Jessica completed her Ph.D. in 2012, with the focus of microRNA expression in prostate cancer. Her primary area of expertise is molecular studies in urological cancers, and she currently focuses on the role of inflammation and immunity in cancer development and progression.



    Abstract
    χ

    Abstract

    Jessica Carlsson
    Orebro University, Sweden

    Renal cell carcinoma (RCC) is the most common renal tumor, consisting of ~3% of all malignancies worldwide. The prognosis of RCC can vary widely, and detecting patients at risk for recurrence at an early stage could improve the outcome for the patient. The factors used in the clinics today cannot reliably predict the natural history of the disease, thus there is a need for finding new biomarkers that can aid in predicting patient outcome. Several studies indicate that miRNAs are potential candidates as prognostic biomarkers for patients suffering from RCC. The aim of this study was to validate the potential of miR-126 to predict prognosis in a Swedish cohort of RCC patients. Methods: The expression of miR-126 was measured using quantitative PCR (qPCR) in formalin-fixed paraffin-embedded (FFPE) tumor tissue from 116 patients diagnosed with RCC between 1987 and 2010. Results: miR-126 was found to be differentially expressed between malignant and adjacent benign tissue. The expression of miR-126 was also differentially expressed between tumor grades, and stages of RCC. We could furthermore show that in a univariate model, a low expression of miR-126 was associated with shorter time to recurrence of the disease. Conclusion: Our results indicate that miR-126 expression has a potential to be used as a prognostic biomarker for patients suffering from RCC. However, further studies are needed in order to confirm these results.

    Time:
    12:40-13:05

    Title: A Novel Cellular Crosstalk Promoting Tumor Progression and Metastasis

    Andrei V. Bakin
    Roswell Park Cancer Institute, Buffalo, New York

    Biography
    χ

    Biography

    Andrei V. Bakin
    Roswell Park Cancer Institute, Buffalo, New York

    Professor Andrei Bakin has received a doctoral degree from Moscow Lomonosov University. He was trained in cancer research with Professor Tom Curran at St. Jude Children’s Research Hospital, and in breast cancer with Professor Carlos Arteaga at Vanderbilt University. He is currently a principal investigator at Roswell Park Cancer Institute. Dr. Bakin has done pioneering studies on EMT in cancer progression and metastasis. His group has identified novel therapeutic targets driving metastasis to the bone and lungs. He has mentored over ten graduate students. He is also a member of Editorial Board of several scientific journals and active member of AACR.



    Abstract
    χ

    Abstract

    Andrei V. Bakin
    Roswell Park Cancer Institute, Buffalo, New York

    Treatment of cancer patients with advanced or recurrent disease presents a considerable challenge. The reasons behind disease progression and spread are not fully understood. Our goals are to define what drives metastatic progression and to develop novel therapies that would eliminate the mortality associated with metastatic disease. Emerging data support a key role of the tumor microenvironment (TME) in cancer progression, development of metastases, and response to therapy. Research indicates that tumor cells are involved in a complex and dynamic crosstalk with various cellular components of TME. Our team investigates the interaction of tumor cells with tumor-associated fibroblasts in breast carcinoma models. We have recently reported that the interaction of tumor cells with fibroblasts alters production and signaling by pro-inflammatory cytokines, e.g. TNF and IL1, and anti-inflammatory TGF-β cytokines. Our studies revealed that the cytokine crosstalk may exert synergistic and neutral (cytokine-specific) responses. The overall force of these complex interactions leads to promotion of tumor blood vessels through a process of angiogenesis, changes in fibrotic material, and alterations in immune cell populations within the TME. The lecture will present updates on the molecular details underlying these cellular and cytokine interactions. We will also discuss the translational implications of our research and potential new venues for therapeutic intervention into cancer progression.

    Time:
    14:05-14:30

    Title: PD-L1 Expression is Associated with Poor Prognosis in Renal Cell Carcinoma

    Sabina Davidsson
    Orebro University, Sweden

    Biography
    χ

    Biography

    Sabina Davidsson
    Orebro University, Sweden

    Sabina Davidsson work as a researcher at the department of Urology at the University Hospital of Orebro, Sweden. She defended her thesis “Infection induced chronic inflammation and its association with prostate cancer” 2013. The current focus of her research concerns which role different immune/inflammatory cells plays in the development of a number of urological cancer types, including renal cancer, penile cancer, bladder cancer, and prostate cancer.



    Abstract
    χ

    Abstract

    Sabina Davidsson
    Orebro University, Sweden

    Programmed death ligand 1 (PD-L1) is an immunosuppressive membrane protein which, when interacting with its receptor programmed death 1 (PD-1), acts as a negative regulator of the anti-tumor T cell-mediated immune response. Overexpression of PD-L1 in different malignancies such as melanoma and gastric cancer is associated with poor clinical outcomes. The prognostic value of PD-L1 expression in renal cell carcinoma (RCC) has been controversial to some extent. In this study, the prognostic value of PD-L1 expression in RCC was evaluated by analyzing PD-L1 immunoreactivity in tumor cells and tumor infiltrating immune cells (TIICs) in 358 RCC patients with long term follow-up. Since the discrepancy between previous studies may be due to the lack of standardized methodology for evaluating PD-L1 expression by immunohistochemistry, the agreement between two anti-PD-L1 antibody clones, 28.8 and SP142, was also compared. PD-L1 positivity in tumor cells was associated with higher Fuhrman nuclear grade (p<0.001), recurrence (p=0.006), and death due to RCC (p=0.05). PD-L1 positivity in TIICs was associated with higher Fuhrman grade (p<0.001), higher AJCC-stage (p=0.019), and death due to RCC (p=0.001). A multivariate regression analysis revealed a significant positive association of time to cancer-specific death with both PD-L1 positive tumor cells and TIICs (p= 0.014 and p= 0.004, respectively). To conclude, RCC patients with PD-L1 positive tumor cells and TIICs are at significant risk for cancer progression, and the expression of PD-L1 on those cell types may be used as a complementary prognostic factor in the management of RCC patients.

    Time:
    14:30-14:55

    Title: Anti-FIRs (PUF60) Auto-Antibodies were Detected in the Sera of Early-Stage Colon Cancer Patients. Identification of Specific and Common Diagnostic Antibody Markers for Gastrointestinal Cancers by SEREX Screening Using Testis cDNA Phage Library

    Kazuyuki Matsushita
    Chiba University Hospital, Japan

    Biography
    χ

    Biography

    Kazuyuki Matsushita
    Chiba University Hospital, Japan

    Kazuyuki Matsushita was born in the City of Chiba, neighbor of Tokyo area, Japan. In 1988, graduated from Chiba University and was awarded with MD. In 1995 maintained his PhD at the Graduate Scholl of Medicine, Chiba University in Japan. From 1997 through 2000 was a visiting fellow, of the NCI, NIH, USA. In 2015, he was listed as a Board of Laboratory Medicine, Japanese Society of Laboratory Medicine, Japanese Board of Medical Genetics, form the Japan Society of Human Genetics. In 2010, he got the Board of Specialty in Cancer Treatment from Society of Japanese Cancer Treatment Society. At present he is a Professor of Department of Laboratory medicine, Director of Laboratory Medicine, Division of Clinical Genetics and Proteomics, Chiba University Hospital, Chiba, Japan. He has been studying c-myc transcriptional regulation, especially demonstrated on c-myc transcriptional repressor FIR (FBP interacting repressor) in carcinogensis. Proteomic and genomic analysis in cancinogenesis and DNA damage repair pathway for clinical validities such as cancer treatment and diagnosis. Establishment of biobanks network of human clinical samples in Japan for novel biomarkers research are studied in his group.



    Abstract
    χ

    Abstract

    Kazuyuki Matsushita
    Chiba University Hospital, Japan

    Anti-PUF60, poly(U)-binding-splicing factor, autoantibodies are reported to be detected in the sera of dermatomyositis and Sjogren’s syndrome. PUF60 is identical with far-upstream element-binding protein-interacting repressor (FIR) that is a transcriptional repressor of c-myc gene. In colorectal cancers, a splicing variant of FIR that lacks exon2 (FIRΔexon2) is overexpressed as a dominant negative form of FIR. The autoantibodies for FIRs were examined in the sera of 87 colorectal cancer patients. Anti-FIRs antibodies were surely detected in the preoperative sera of 28 colorectal cancer patients (32.2% of positive rates), and the detection rate was significantly higher than that in healthy control sera by Alpha (amplified luminescent proximity homogeneous assay)-LISA assay. The level of anti-FIRs antibodies significantly decreased after the operation. Furthermore, the area under the curve of receiver operating characteristic for anti-FIRs antibodies was significantly larger (0.85) than that for anti-p53 antibodies or CA19-9. In conclusions, Anti-FIRs antibodies were detected in relatively early-stage colorectal cancers. Further, we have screened autoantibodies by phage expression cloning and identified novel fourteen antigens. As for auto-antibodies against fourteen antigens, Alpha-LISA assay was performed in the sera of gastrointestinal cancers patients to confirm the results. Serum antibody levels against these fourteen recombinant proteins as antigens between healthy donors (HD) and esophageal squamous cell carcinoma (ESCC) patients, gastric cancer (GC), or colon cancer (CC) were compared. Receiver operating curve (ROC) revealed similar results except CCNL2 in CC. AUC values calculated by ROC were higher than 0.7 in TPI1, HOOK2, PUF60, PRDX4, HS3ST1, TUBA1B, TACSTD2, AKR1C3, BAMBI, DCAF15 versus ESCC, TPI1, HOOK2, PUF60, PRDX4, TACSTD2, AKR1C3, BAMBI, DCAF15 versus GC, and TPI1, HOOK2, PUF60 versus CC. AUC of the combination of HOOK2 and p53 antibodies versus ESCC was observed to be as high as 0.8228. Higher serum antibody levels against 10 antigens could be potential diagnostic tool for ESCC. Higher serum antibody levels against 8 antigens could be potential diagnostic tool for GC, and serum antibody levels against 3 antigens could be potential diagnostic tool for CC. Keywords auto-antibody, cancer biomarker candidate, colorectal cancer, far-upstream element-binding protein-interacting repressor (FIR); poly(U)-binding-splicing factor (PUF60).

    Time:
    14:55-15:20

    Title: NGS Approach for New Ovarian Cancer Biomarker Discovery

    Stefania Brandini
    National Research Council (ITB-CNR), Bari, Italy

    Biography
    χ

    Biography

    Stefania Brandini
    National Research Council (ITB-CNR), Bari, Italy

    Stefania Brandini is a biologist with a Ph.D. in ‘Genetics, Molecular and Cellular Biology’ obtained in January 2017 at the University of Pavia. Since 2010 she worked and collaborated with different research teams acting in various environments (i.e. University, hospital and CNR) and experienced the methods used in genetics and molecular biology. Recently, she focused on cancer epigenetics and in particular on the characterization of new biomarkers useful for the diagnosis/prognosis/therapy of proliferative diseases by NGS methods. She was co-author of 6 original articles, 2 of which selected for the covers of the journal Molecular Biology and Evolution



    Abstract
    χ

    Abstract

    Stefania Brandini
    National Research Council (ITB-CNR), Bari, Italy

    Ovarian cancer is the sixth most common cancer in women and is called ‘the silent killer’ as most women are not diagnosed until the cancer has already spread, thus resulting in low chances of survival. Given the complex and heterogeneous nature of this neoplasm, it is crucial the identification of molecular biomarkers that might be used for focused and efficient diagnosis, prognosis and therapy. In order to contribute to the identification of new biomarkers for ovarian cancer, we used the Next Generation Sequencing (NGS) technology allowing simultaneous testing of the coding and non-coding RNAs from 21 samples belonging to the most representative histological types of ovarian, serous and endometrioid carcinomas. Among the molecular factors involved in the process of tumor transformation, many small noncoding miRNAs and their target genes have been found. Some of these genes have already been reported to be involved in cell proliferation and death pathways, and might be considered as possible targets for specific treatment purposes. The differentially expression analysis revealed more than one thousand mismatches in the tumor expression profiles of both long and miRNAs in comparison to the control tissues. These data shed light on new possible molecular biomarkers for ovarian cancer.

    Time:
    15:20-15:45

    Title: Pancreatic Ductal Adenocarcinoma (PDAC): The Patient´s Journey and Highest Unmet Need

    Lubos Petruzelka
    Charles University, and General University Hospital in Prague, Czech Republic

    Biography
    χ

    Biography

    Lubos Petruzelka
    Charles University, and General University Hospital in Prague, Czech Republic

    Professor Petruzelka graduated as MD from First Medical Faculty of Charles University in 1976, achieving PhD at the same Institution in 1997. He is certified specialist in Radiotherapy and in Medical Oncology (including ESMO Certification in 1995). Since 2001 he works as head of Department of Oncology, First Faculty of Medicine, Charles University, and General University Hospital in Prague and also head of Institute for Radiation Oncology and Department of Oncology First Faculty of Medicine Military Hospital in Prague. Professor Petruzelka is actively involved in pre-gradual and post-gradual teaching and academic activities in clinical oncology and in 2008 was designated as Professor of Medicine and Oncology at Charles University in Prague. His major clinical and research interests include area of gastrointestinal and lung cancer, new drugs, targeted therapy, immunotherapy of solid tumours and predictive oncology.He is currently member of the board of Czech Society of Clinical Oncology and member of other international Societies (ASCO, EORTC, AACR, SITC). He was a national representative of the Czech Republic in ESMO. He is an active member PCE platform (pancreaticcancereurope). He is also active as member of CELC-Central European Lung Cancer board and as member of scientific and educational board of CECOG – Central European Cooperative Oncology Group. He is author of numerous scientific publications and chapters in medical books, chairman of international editorial board for Central European version of Lancet Oncology and member of editorial boards in Magazine of European Medical Oncology and local professional journals (Journal of Czech Physicians, Clinical Oncology, Oncology Care).



    Abstract
    χ

    Abstract

    Lubos Petruzelka
    Charles University, and General University Hospital in Prague, Czech Republic

    PDAC outcomes are unyieldingly poor even despite improvement in the overall picture for many cancers. Stage for stage, PDAC is associated with the lowest survival rates of any major cancer type. There has been little progress in improving outcomes over the past years and remains one of the most deadly cancers. Reasons for this include the lack of early detection and effective treatments. PDAC is the only one of the top five cancer killers for which deaths are projected to increase. Such figures justify the positioning of PDAC as a cancer of significant unmet need. The early detection: The best chance for curing the disease is early detection. PDAC is relatively uncommon, the average person has only a 1% chance developing PDAC over life time. General screening is not recommended and the future is in selective screening of people who are at high risk for malignant tumours to detect premalignant tumours or early stage potentially curable by surgery. The total diagnostic interval is longer for PDAC than for other cancers. The diagnostic workup time to the start of treatment should be as short as possible, less than one month since the occurrence of the initial suspicious findings. Biomarkers for early detection: There remains no clinically useful test today to detect early PDAC and/or high-grade PanINs. Treatment: Parallel improvements in systemic and locoregional therapies and rapid implementation of novel therapeutics to clinical practice are needed. There is no effective targeted therapy available in the clinics and immunotherapy has so far disappointed. Conclusion: PDAC remains a difficult, and growing, problem in oncology. We are now better understanding the biology, especially with respect to genomic (both somatic and germline) alterations as pathogenic, predictive, and prognostic factors. The ultimate goal of considerable improvement in clinical outcomes will require continued scientific and clinical investigations, multidisciplinary care of patients, and focus on collaborative research across various institutions.

    Time:
    15:45-16:10

    Title: Evaluation of the Predictive and Prognostic Role of Bcl2 in Non-Metastatic Locally Advanced Triple-Negative Breast Cancer Patients: A Clinicopathologic and Immunohistochemical Study

    Asmaa Elkady
    Tanta University, Egypt

    Biography
    χ

    Biography

    Asmaa Elkady
    Tanta University, Egypt

    Asmaa Mohamed Elkady, MD of Clinical Oncology 2015, Lecturer of Clinical Oncology, Faculty of medicine, Tanta University, Egypt - Cairo



    Abstract
    χ

    Abstract

    Asmaa Elkady
    Tanta University, Egypt

    Breast cancer is considered to be a common malignancy and the second most common leading cause of cancer death in females. So, continuous researches for new prognostic markers which will aid in therapy is mandatory . Bcl2 has been associated with estrogen receptor positivity and good prognosis in breast cancer. However contradictory data have been reported in several studies concerning the role and the prognostic impact of this marker in triple-negative breast cancers (TNBCs). The aim of this work is to study the expression of Bcl2 in locally advanced non-metastatic TNBCs and to correlate these data with clinicopathologic findings and patient disease free survival (DFS) to assess its prognostic significance. In addition to evaluate the role of Bcl2 as a surrogate predictive marker of response to neoadjuvant chemotherapy. Patients & Methods: Paraffin blocks obtained from 61 female patients with non-metastatic locally advanced invasive TNBCs were analyzed for Bcl2 immunohistochemical expression. All patients treated by neoadjuvant chemotherapy (NAC), with a sequential regimen containing anthracycline and taxanes -based regimen at Clinical Oncology Department, Faculty of Medicine, Tanta University Hospital during the period between January 2009 and December 2014. Results: The study included 61 female patients with non-metastatic locally advanced TNBCs. BCL2 showed positivity in 29 cases (47.54%). BCL2 was inversely correlated with response to neoadjuvant chemotherapy (P = 0.005). Tumor grade showing a border line significant correlation with it, with a higher frequency of grade III cancers being BCL2 negative (p= 0.0598). There was no statistical significance when looking at the correlation between BCL2 positivity and tumor size, (p= 0.807), nodal status (p= 0.948), age (p= 0.933), as well as lympho-vascular invasion (p= 0.705). The 1 year, 2 year, and 3 year DFS for patients whose tumors are positive for BCL2 without residual disease after neoadjuvant chemotherapy was 92 %, 81% and 70% compared to 91%, 80% and 65% for the women with BCL2 negative tumors, respectively. (P = 0.799). The 1 year, 2 year, and 3 year DFS for patients whose tumors are positive for BCL2 with residual disease after neoadjuvant chemotherapy was 95 %, 79% and 70% compared to 85%, 53% and 40% for the women with BCL2 negative tumors, respectively. (P = 012). Conclusion: In TNBC patients, adding Bcl2 to the panel of markers used in current clinical practice could provide prognostic and predictive information. Bcl2 appears to be potentially useful marker of good prognosis in patients with non-metastatic locally advanced TNBCs who had residual disease , with a sequential regimen containing anthracycline and taxanes -based regimen and can be used to detect cases with aggressive biological behavior that can benefit from more aggressive therapy.

    Time:

    Title: Expression of Podoplanin in Laryngeal Squamous Cell Carcinoma and Dysplasia

    Rasha Ahmed Khairy
    Cairo Unversity, Egypt

    Biography
    χ

    Biography

    Rasha Ahmed Khairy
    Cairo Unversity, Egypt

    Rasha Ahmed Khairy has completed her M.D at the age of 33 years from Faculty of medicine, Cairo University . She is lecturer of pathology in faculty of medicine, Cairo University.She has published 9 papers in reputed journals and has joined as a reviwer in reputed journal.



    Abstract
    χ

    Abstract

    Rasha Ahmed Khairy
    Cairo Unversity, Egypt

    In human cancers, podoplanin expression and its correlation with tumour invasive potential raise its possible role as a diagnostic and prognostic marker for cancer.Aim:To investigate the immunohistochemical expression of podoplanin in laryngeal Squamous Cell Carcinoma (SCC) and dysplasia.Materials and Methods:This study included a total of 60 archived, formalin fixed, paraffin embedded tissue blocks of 40 cases of laryngeal SCC and 20 cases of dysplastic lesions. The samples were immunohistochemically analysed for podoplanin expression.Results:Podoplanin expression was significantly higher in laryngeal SCC (90%) than laryngeal dysplastic lesions (55%) (p-value=0.002). The expression of podoplanin was significantly increased with the higher grades of dysplasia (p-value=0.016). A significant positive correlation was detected between podoplanin expression in laryngeal SCC and depth of tumour invasion (p-value=0.035), and stage (p-value=0.026).Conclusion:The high expression of podoplanin in laryngeal SCC and its significant correlation with poor prognostic parameters recommends podoplanin as a prognostic marker in laryngeal SCC. In addition, increased podoplanin expression with higher grades of dysplasia, supports its role in malignant transformation and allows us to recommend its evaluation in premalignant lesions.Keywords: Immunohistochemistry, Invasive potential, Laryngeal carcinoma, Malignant transformation

  • Sessions:
    Cancer Etiology and Epidemiology & Radiation, Surgical and Medical Oncology & Clinical Research & Cancer Immunology & Cancer Drug Discovery, Development and Delivery

    Time:

    Title: Identification of a Native Novel Oncolytic Immunoglobulin on Colon Epithelial Cells: An IgA/IgG Bispecific Heterodimeric Chimera

    P. Padmanabhan Nair
    The Johns Hopkins University Bloomberg School of Public Health and NonInvasive Technologies LLC, USA

    Biography
    χ

    Biography

    P. Padmanabhan Nair
    The Johns Hopkins University Bloomberg School of Public Health and NonInvasive Technologies LLC, USA

    Padmanabhan Nair, Ph.D., FAAAS has done his B. Sc.(1946)University College, Travancore University, Trivandrum, Kerala, India; M.Sc, (1954) Ph.D. (1956) Royal Institute of Science, Bombay (Mumbai), India; Research Officer, (1958-1960) All-India Institute of Medical Sciences, New Delhi, India; Fulbright Scholar and McCollum-Pratt Fellow,(1960-19963) The Johns Hopkins University, Baltimore, Maryland; Head of Medical Research,(1963- 1983) Sinai Hospital of Baltimore, Inc; Research Scientist (1983-1998) Beltsville Human Nutrition Research Center, ARS, USDA, Beltsville, Maryland; Founding President and CEO, (2000) NonInvasive Technologies LLC, Elkridge, Maryland; Adjunct Professor of International Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland.



    Abstract
    χ

    Abstract

    P. Padmanabhan Nair
    The Johns Hopkins University Bloomberg School of Public Health and NonInvasive Technologies LLC, USA

    The colonic mucosa undergoes rapid renewal with a turnover rate of approximately five days. Conventional dogma has contended that these mucosal cells after exfoliation undergo apoptosis and are excreted in a necrotic state. In 1991 we provided evidence that showed that these cells in large measure transit the fecal stream intact and viable and can be isolated from stool samples for further investigation. We developed a robust technology to isolate millions of these cells from small aliquots (0.5 gm) of fresh stool samples and examine them for biomarkers and other characteristics. This technology, that we termed COPROCYTOBIOLOGY allowed us to assess the expression of a number of biomarkers among which we identified IgA and a subpopulation of cells that co-expressed both IgA and IgG. This heterodimer was then shown to mediate a broad spectrum cytotoxicity against human tumor cells. In tissue culture these cells continued to generate this chimeric antibody over several generations. When we screened a cohort of about 60 subjects we observed a total absence of this immunoglobulin in two individuals of African/American origin suggestive of a germline deletion in these subjects.

    Time:

    Title: Cancer Cell-derived IL-6 Promotes MDSC, TAM, PD-1 Expression in Peripheral Blood Mononuclear Cells

    Ge Jin
    Case Western Reserve University, USA

    Biography
    χ

    Biography

    Ge Jin
    Case Western Reserve University, USA

    Ge Jin, Ph.D., is an Associate Professor in the Department of Biological Sciences, Case Western Reserve University School of Dental Medicine, USA. Dr. Jin’sresearch interest focuses on the mechanism underlying cancer cell-derived cytokines and/or metabolites and immune response and the role of HIV-infection in the development and progression of non-AIDS-defining cancers.



    Abstract
    χ

    Abstract

    Ge Jin
    Case Western Reserve University, USA

    Monocytes, myeloid derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) have emerged as key immune modulators in various tumor models and human malignancies that suppress innate and adaptive immunity to support tumorigenesis. Programmed Cell Death Protein 1 (PD-1), which is up-regulated on T cells upon activation and remains high on exhausted T cells, also plays critical roles in immunosuppression. The increased presence of MDSCs, TAMs and PD-1 in the tumor is associated with progression of disease and poor prognosis in several cancer types. However, the mechanism remains unclear. We used conditioned media (CM) from head and neck cancer (HNC) and lung cancer cell lines to treat peripheral blood mononuclear cells (PBMCs) and found that the CM treatment increased the population of MDSCs (Lin-/CD11b+/CD33+/HLA-DR–) and TAMs (CD11b+/CD68+/CD163+) in PBMCs. We assessed the expression of inflammatory cytokines in cancer cells associated with PBMC PD-1 and its ligands PD-L1 and PD-L2, Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4), Lymphocyte-Activation Gene 3 (LAG-3), T-Cell Immunoglobulin and Mucin-Domain Containing-3 (TIM-3), and cytokines. We found that the CM from all cancer cell lines significantly stimulated expression of IL-1β, PD-1, and CTLA-4 in PBMCs. Most importantly, we discovered that IL-6, but not IL-4, was significantly elevated in cancer cell CMs and played a major role in promoting the immunosuppressive phenotype of PBMCs. In this study, we provide evidence that cancer cell-derived IL-6 increases the population of MDSCs, TAMs, PD-1- and PD-L1-expressing immune cells, thereby establishing an immunosuppressive tumor microenvironment for progression.Supported by NIH R01DE025284 (GJ)

    Time:

    Title: Synergistic Effects of Oncolytic Virotherapy in a Bortezomib Resistant Syngeneic Mouse Model of Multiple Myeloma is Mediated Via Immune Modulation

    Chandini Thirukkumaran
    Tom Baker Cancer Centre, University of Calgary, Canada

    Biography
    χ

    Biography

    Chandini Thirukkumaran
    Tom Baker Cancer Centre, University of Calgary, Canada

    Dr. Chandini Thirukkumaran is a Research Associate Professor at the Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta. She received her PhD in microbiology in 1994 from the University of Calgary. Following completion of a post- doctoral fellowship in signal transduction at the University of Calgary she joined the Translational Research Laboratories at the Tom Baker Cancer Centre, Calgary as a Research Assistant Professor in 1999. Since then her work has focused on oncolytic viruses as treatment modality for cancer. Presently she is conducting research on multiple myeloma and breast cancer and the effects of oncolytic viruses on immune modulation when given in conjunction with “standard of care therapies” for these malignancies



    Abstract
    χ

    Abstract

    Chandini Thirukkumaran
    Tom Baker Cancer Centre, University of Calgary, Canada

    Introduction: Multiple myeloma (MM) is a plasma cell neoplasm that is considered incurable. Despite the advent of new agents the majority of MM patients relapse secondary to therapy resistance. The potential of reovirus (RV) as a novel therapeutic agent for MM under in vitro, in vivo and ex vivo conditions has been demonstrated by us and a phase I clinical trial of MM with RV therapy has shown indications of efficacy. Utilizing the syngeneic transplantable Vk*MYC bortezomib (BTZ) resistant MM mouse model, we demonstrate that mice harbouring BTZ insensitive MM tumors significantly respond to RV+BTZ combined treatment better than monotherapy. Our data indicate that this RV+BTZ synergy is manifested via, direct oncolysis in conjunction with enhanced immune activation. Methods: C57BL/6 wt mice were divided into 2 groups and transplanted with Vk*MYC myeloma (Vk12598) and were treated as follows, (N=8): 1) vehicle control (VC), 2) live reovirus (LV), 3) dead reovirus (DV), 4) BTZ, 5) LV+BTZ, 6) DV+BTZ. Mice in group 1 were sacrificed after 4 days of treatment and their spleens and bone marrow (BM) were formalin fixed and paraffin embedded. These were assessed for CD138+ MM tumour as well as viral RNA and protein in the tumour microenvironment (TME) and a variety of immune correlates as well as apoptotic markers. Mice in group 2 were assessed for serum gamma globulins (M-spike) on a weekly basis and overall survival analysis was conducted. Results: Mice treated with RV+BTZ demonstrated highly significant (P<0.001) reductions in their M-spikes at 3 and 4 weeks post treatment and superior overall survival (P<0.001). Analysis of tumour viral delivery/replication and immune activation in the TME as early as 4 days post treatment initiation indicated significant (P<0.01) viral replication, caspase 3 activity, CD3+ and NK cell accumulation in the RV+BTZ treatment. Conclusions: Our data indicate that this RV+BTZ synergy is manifested by enhanced apoptosis, successful viral delivery via tumour associated endothelial and follicular dendritic cells and immune modulation. Since the progression of MM is associated with concomitant immune suppression and drug resistance, these results have significant implications for shaping future clinical trials.

    Time:

    Title: HER-2 B Cell Epitope Peptide-Based Cancer Vaccines and Combination Immunotherapies with EGFR, HER-3, IGF-1R, VEGF and a novel PD-1 Vaccine

    Pravin T. P Kaumaya
    The Ohio State University Medical Center and the James Comprehensive Cancer Center, USA

    Biography
    χ

    Biography

    Pravin T. P Kaumaya
    The Ohio State University Medical Center and the James Comprehensive Cancer Center, USA

    Dr. Kaumaya is Professor of Medicine in Department of Ob/Gyn at the OSU Wexner Medical Center and the James Comprehensive Cancer Center. Dr Kaumaya is internationally recognized as an expert in the fields of vaccine research with emphasis on peptide vaccines for cancer, viral diseases as well as peptide therapy for autoimmune diseases. He conducts research in the areas of tumor immunology, mechanisms of tumor cell-immune cell interactions, and immune mechanisms. The laboratory functions as an integrated translational research program with the goal of designing and developing new immunotherapies and immunologic strategies for cancer treatment and prevention. He is an inventor on several issued and pending patents for Peptide Vaccines and Therapeutic Technologies.



    Abstract
    χ

    Abstract

    Pravin T. P Kaumaya
    The Ohio State University Medical Center and the James Comprehensive Cancer Center, USA

    We have created and established a portfolio of validated B-cell peptide epitopes against multiple receptor tyrosine kinases to expedite the development of new paradigm shifting cancer immunotherapies. We have identified the most biologically effective combinations of EGFR (HER-1), HER-2, HER-3, VEGF, IGF-1R and PD-1 peptide vaccines/mimics to selectively inhibit multiple receptors and signaling pathways. We have translated two HER-2 combination peptide vaccines to the clinic in a Phase 1/2b trial to safely deliver curative and transformative cancer immunotherapies to advanced cancer patients. The potential safety, efficacy, durability, usability and cost a B-cell peptide vaccine may/could benefit a variety of patients: Stimulates the immune system to produce natural Abs, potentially safer, Stimulates the immune system to produce natural Abs, potentially safer, Antibodies continuously produced a lasting immune response to inhibit tumor recurrence, Antibodies continuously produced a lasting immune response to inhibit tumor recurrence. This presentation will detail our clinical trial and basic studies based on the development of combinatorial immunotherapeutic strategies that act synergistically to enhance immune-mediated tumor killing aimed at addressing mechanisms of tumor resistance for several tumor types. We will discuss the novel combinations of HER-2 and PD-1 vaccines.

    Time:
    12:20-12:45

    Title: Translation of Laboratory Research Findings towards Cancer Risk Assessments from Environmental Chemicals

    David W. Hein
    University of Louisville, USA

    Biography
    χ

    Biography

    David W. Hein
    University of Louisville, USA

    Dr. Hein serves as Peter K. Knoefel Endowed Chair of Pharmacology, Professor and Chairman of the Department of Pharmacology & Toxicology, and Distinguished University Scholar at the University of Louisville (USA). His research program includes studies of the molecular epidemiology of cancer susceptibility, pharmacogenetics, genomics, personalized medicine, and functional genomics. He has coauthored over 240 peer-reviewed journal articles and book chapters, 75 published gene sequences, and over 600 abstracts. The publications have over 13,000 citations with an h-index 58. He has served as principal investigator/co-investigator/mentor on over 75 research grants and contracts totaling over $50 million dollars.



    Abstract
    χ

    Abstract

    David W. Hein
    University of Louisville, USA

    Human epidemiological studies associating chemical exposures to cancer risk often are inconsistently validated across studies. Examples include the effect of smoking on cancer etiology other than the lung, such as urinary bladder and breast. Research findings from the laboratory have improved the understanding of arylamine carcinogen metabolism leading to improved design and interpretation of human molecular epidemiology investigations. Laboratory studies that infer and test biological plausibility, including cancer risks modified by differential metabolism of arylamine carcinogens in rapid and slow arylamine N-acetyltransferase (NAT2) acetylators, have been critical for investigating the role of smoking in the etiology of human cancers. These concepts will be explored with an example of a cancer in which the role of smoking has largely been validated (urinary bladder cancer) and an example where a consensus for the role of smoking remains to be achieved (breast cancer).

    Time:
    12:45-13:10

    Title: Epidemiology and the Etiology of HPV Induced Cervical Cancer: A Cohort Study in Eastern Uttar Pradesh, India

    Jagat K Roy
    Banaras Hindu University, India

    Biography
    χ

    Biography

    Jagat K Roy
    Banaras Hindu University, India

    Jagat Kumar Roy is a Professor of Zoology in Banaras Hindu University teaching Genetics and Developmental Biology. In research front, lab has shown involvement of Rab11, a small G-protein, in membrane morphogenesis and differentiation in Drosophila. Also a new tumour suppressor function has been assigned to Dcp2 in Drosophila besides its function of decapping of mRNA. Epidemiology of HPV in human cervix cancer and in understanding the role of some of the cellular factors in HPV induced cervical cancer is in progress. 13 students dis Ph D from the lab and 49 publications came including a small paper in Nature.



    Abstract
    χ

    Abstract

    Jagat K Roy
    Banaras Hindu University, India

    Apart from the numerous risk factors associated, HPV alone accounts for more than 95% of cervical cancer. Epidemiological studies in 2424 women in eastern Uttar Pradesh from differing socio-demographic strata showed HPV16 to be most prevalent (63.7%) strain, followed by HPV 31(6.7%). Focusing on the role of host cellular factors during tumourigenesis, identified transcription factors, BRN3A and WWOX, to be differentially expressed in a number of other tumours. Analysis of HPV positive cell lines shows that BRN3A does not interact with activated HIPK2, undergoes positive auto-regulation and remains unaltered in presence of cisplatin. Screening of sensory enhancer region of BRN3A led to the identification of a novel SNP at 60163379 A>G, with the frequency of G allele being 8.73%. Silencing of BRN3A in cervical cancer cell lines led to down-regulation of the factors instrumental in the process of angiogenesis, viz., VEGF, HIF-1α, ANGPT2 and FGF-2. This brings to light the involvement of the oncoprotein, BRN3A, in neovascularization process in uterine cervix cancer cells. However, the transcription factor WWOX, showed a significantly decreased protein level despite its elevated transcript levels. Taken together, our study opens up further avenues in the exploration of HPV induced cervical carcinogenesis to delineate the interacting partners of HPV.

    Time:
    14:10-14:35

    Title: Personalized Therapy in Oncology: Progress, Challenges and Opportunities

    Sherry Bradford
    AccuTheranostics Inc., USA

    Biography
    χ

    Biography

    Sherry Bradford
    AccuTheranostics Inc., USA

    Dr. Sherry Bradford attended undergraduate school at SUNY at Buffalo and was awarded a full tuition scholarship to pursue her PhD graduate degree (Biochemistry) from the University of Buffalo/ Roswell Park Cancer Institute Division of SUNY at Buffalo School of Medical and Biomedical Sciences. During her clinical laboratory vocation, she was solicited by the Chief of Surgery at Millard Fillmore Hospital, Buffalo, NY, to direct the Surgical Research laboratory. There she successfully led the research on the use of human microvascular umbilical cord endothelium for lining stents. She was further awarded the “1st Place - Award for Excellence in Research” from the American Federation for Clinical Research, and the “1st Place - Award for Excellence in Research” – SUNY at Buffalo, Roswell Park Cancer Institute Research Forum. In 2008, Dr Bradford and colleagues form AccuTheranostics and the idea of Oncology Personalized Medicine (PM) based on the specific patient’s own biochemical and genetic profile to administer personized treatment regimens. An in vitro chemosensitivity test on tumor cells, using flow cytometric methodologies, was developed and is currently being evaluated by the NYS-DOH for clinical utility. At present, the research division of AccuTheranostics is in the throngs of developing at least 3 novel PM assays for translation into clinical status. Dr. Bradford sits on the EDITORIAL BOARD of theInternational Journal of Medical and Health Sciences Research; on the EDITORIAL BOARD ofInsights inCancer Research, Editorial Board Member (Editor-in-Chief) for the Scientific Federation of Oncology & Cancer: Editorial Board Member of the Journal of Biomolecular Research and Therapy; and has authored and co-authored a number of scientific peer-reviewed manuscripts. She is also a member of many professional organizations including (but not limited to): International Metabolic Cancer Group, AACR, ASCO, and GLIFCA. Shehas been and will be an invited speaker at various domestic and international scientific meetings including:Invited Speaker: Proceedings of the 6th Int’l Conf on Frontiers of Polymers and Adv Materials, Recife, Brazil, March 2001; Key Note Speaker: Cancer Science 3rd World Congress Oct. 21, 2013 – San Francisco, CA; Plenary Speaker, Cancer Science 4th World Congress: Valencia, Spain, Sept. 1-3, 2015;International Expert and Key Note Speaker: INDO-GLOBAL HEALTHCARE SUMMIT & EXPO 2014, Hyderabad, India from July 23-26, 2015;Key Note Speaker: Dubai, United Arab Emirates, Aug 27-29, 2015; Keynote Speaker Gynecologic Oncology, May 19-21, 2016, San Antonio, Tx. This Year (2017) Keynote Speaker in Rome, Portugal, Dubai, Chicago, San Francisco and Philadelphia. Dr. Bradford also holds one patent: U.S. Patent No. 6485714, Published Patent - Serial No./Application No. 10/340,858, and 3 – patents pending (2017).



    Abstract
    χ

    Abstract

    Sherry Bradford
    AccuTheranostics Inc., USA

    Despite significant increases in the numbers of people surviving cancer, there yet exists a vast rift in the number who die each year despite treatment. It remains one of the most challenging diseases to treat, in part, due to the heterogeneity of the malady. Most cancers originate as a single cell, and thus monoclonal in origin, however, due to innate genetic instability of subsequent cell generations, new characteristics create a heterogenic disease well-defined by genetic clonal expansion epigenetic changes. However, tumors cells are not the only contributors to tumor heterogeneity. There exists a reciprocal and dynamic interaction between the microenvironment constituents, such as infiltrating cells, and juxtapositoned matrices and cells, to produce a distinct individualistic tumor phenotype. The clinical relevance is that this tumor heterogeneity contributes significantly to the efficacy of drug therapy and therefore imparts considerable inter-individual variation in pharmacotherapy and clinical response to a myriad of medications. Thus, this divergence underscores the necessity to personalize therapeutic regimens. This oration, tersely, but-to-the-point, edifies the progress, challenges and opportunities for personalized medicine in oncology.

    Time:

    Title: Exploring the Role of "Glycerine Plus Honey" in Delaying Chemoradiation Induced Oral Mucositis in Head and Neck Cancers

    Birendra Yadav
    B & C Teaching Hospital Nepal, Nepal

    Biography
    χ

    Biography

    Birendra Yadav
    B & C Teaching Hospital Nepal, Nepal



    Abstract
    χ

    Abstract

    Birendra Yadav
    B & C Teaching Hospital Nepal, Nepal

    AIM: To assess the efficacy of adding “Glycerine plus Honey” to standard management protocol, in terms of time to delay in oral mucositis ≥ grade 2. MATERIALS AND METHODS: Hundred patients of oral cavity and oropharangeal cancers, planned for concurrent chemoradiation (Dose: 60–66Gy/30-33fractions/6 weeks) were randomized 1:1 to receive either home-made remedy made of “Glycerine plus Honey” added to the standard management protocol to prevent mucositis versus standard treatment alone. CTCAE v 4 (Common toxicity criteria for adverse events) was used for assessing oral mucositis scores weekly. Chi square test was used to compare mucositis scores, weight loss, opioid use, ryles tube feeding, and unplanned treatment breaks in each cohort. Independent T-test was used to compare means to assess the effect of treatment in delaying mucositis ≥ grade 2. RESULTS: Significantly higher number of patients developed grade ≥ 2 mucositis in control arm [n=43 (86%)] compared to study arm [n=30 (60%)] (p=0.003). CTCAE scores favored Glycerine plus honey at week 4, and on last day of radiotherapy. Whereas, time to first occurrence of oral mucositis grade ≥ 2 was 23.17 (± 1.01) days for study arm [radiation dose 31.67Gy (± 1.44)], it was 20.65 (± 0.8) days for control arm [radiation dose 28.14Gy (± 1.16)] (p=0.05). Study patients had lesser weight loss (2.76Kg) than control subjects (3.9Kg) with p=0.008. There were significantly higher number of patients in control arm who required opioid analgesia, ryles tube insertion and had unplanned treatment breaks, compared to study arm.

    Sessions:
    Organ Specific Cancers and Effects & Cancer Care and Psychological Support & Cancer Metastasis

    Time:
    14:35-15:00

    Title: A Clinical and Morphological Rationale for Lateral Neck Lymph Node Dissections in Children and Adolescents with Papillary Thyroid Carcinoma

    Mikhail Frydman
    Republican Centre for Thyroid Tumors, Belarus

    Biography
    χ

    Biography

    Mikhail Frydman
    Republican Centre for Thyroid Tumors, Belarus

    Minsk Municipal Clinical Hospital for Oncology, Republican Centre for Thyroid Tumors (2002- present): head of the department of pathology. Achievements: certification as a thyro-pathologist in internationally recognized InstitutfürPathologie, Universitätsklinikum Essen, Essen, Germany (2006), Successfully passed the exam in immunohistochemistry for mammary gland carcinoma under the auspices of NordiQC (2014), Degree Doctor of Medicine (oncology) was earned in the year 2015 for a research “Papillary thyroid cancer in children and adolescents: diagnosis, treatment, and prognosis”, Took part in conferences under the auspices of European Thyroid Association, American Thyroid Association, International Academy of Digital Pathology, International Academy of Pathology,and World Congress on thyroid Cancerin the form of abstracts, posters and oral presentations.



    Abstract
    χ

    Abstract

    Mikhail Frydman
    Republican Centre for Thyroid Tumors, Belarus

    In Belarus with many papillary thyroid carcinoma (PTC) cases developedin patients because of the post-Chernobyl irradiation the need for prophylactic dissections of the central and lateral compartments of the neck is never questioned. As a result, we collected hundreds of PTC cases in children and adolescents that provide excellent information on the real initial extent of the disease, subsequent treatment and follow-up. Aims: To identify factors associated with nodal disease (and the degree of their involvement) and to predict the risk of recurrent/persistent disease in this cohort of patients using clinical and morphological characteristics of the primary thyroid tumour and its lymph-node metastases in the central compartment of the neck. Material and Methods: All the patients aged ˂19 years old at presentation with PTC who were treated with total thyroidectomy and lymph nodes dissections (in the central and lateral compartments of the neck) according to the extent of disease at the time of diagnosis (n = 509). Results: The metastatic ratio index (MRI) was an independent variable that potentially influence the decision to carry out lateral lymph nodes compartment surgery in addition to routinely performed central lymph nodes dissection. A nomogram with excellent discriminatory ability and accuracy in predicting probability of ipsi or bi-lateral nodal disease was created. Clinical and pathological characteristics associated with relapse were identified. Conclusion The results of our study allowed us to supplement and refine the algorithms proposed by specialists of the American Thyroid Association.

    Time:
    15:00-15:25

    Title: Body-Mind Interventions for Cancer Patients: Methodological Reflections

    Adriaan Visser
    Pro-health.org, Netherlands

    Biography
    χ

    Biography

    Adriaan Visser
    Pro-health.org, Netherlands

    Adriaan Visser (1941), PhD, studied social psychology at the Free University, Amsterdam (NL). The published thesis (1984) was on the methodology of the measurement of patient satisfaction. Worked the rest of his life mostly as health psychologist, engaged in education of university and high school students (psychology, medical, nursing), research in health care, implementation of health care changes, writing, and editing. Nearly 100 grants have been awarded and a lot articles published on patient education, organization of health care, dental care, diabetes, fibromialgie, psychosocial cancer care, breast cancer, prostate cancer, palliative care, aging, family planning, psycho-neuroimmunology (PNI), depression, mindfulness, complementary medicine, and spirituality.



    Abstract
    χ

    Abstract

    Adriaan Visser
    Pro-health.org, Netherlands

    Objective: Methodological analysis on the content, results and limitations of three body-mind interventions for cancer patients. Methods: A secondary analysis of the research designs, patient characteristics, evaluation, and effects of three body-mind interventions for cancer patients: haptotherapy (N= 57) and two studies applying relaxing face massage (N=34 and 79). Different experimental designs have been applied. A variety of well-being effect measures were used. Result: The three appreciated interventions showed limited effects after controlling for confounding factors. The drop-out, differences in severity of cancer, the use of other complementary approaches, and response shift may have affected the found effects. Conclusions: Body-mind interventions require more methodological reflections to develop attractive and effective interventions for cancer patients. Attention need to be paid to measuring short term effects, practically fitting research designs, and response shift. Practice implications: Body-mind approaches are needed to compensate the lack of attention to intentionally body contact of cancer patients during illness and treatment. Body-mind interventions should be intensive, repeated and not too short. The implementation of effective body-mind interventions requires attention to several organizational factors in the health care.

    Time:
    15:25-15:50

    Title: Isolation, Identification of a Flavonoid and Antitumor Activity in Lung Cancer

    Rafael Silva Torres
    Instituto Politecnico Nacional, Mexico City

    Biography
    χ

    Biography

    Rafael Silva Torres
    Instituto Politecnico Nacional, Mexico City

    Rafael Silva Torres has completed his PhD. From Escuela Nacional de Ciencias Biológicas of National Polytecnic Institute and abroad studies M. Phil of Medicinal Chemistry from Loughborough University of Technology Great Britain and sabbatical year from Museum Nacional D´Histoire Naturelle Paris France. He has been working on lung, cervical and breast cancer since 2008. He is membership of American Association of Pharmaceutical Scientists and American Chemical Society. He is investigating the antitumor properties of medicinal plants such as: Sedum praealtum DC. Stenocereus griseus an Annona muricate.



    Abstract
    χ

    Abstract

    Rafael Silva Torres
    Instituto Politecnico Nacional, Mexico City

    The use of Traditional Medicine in Mexico is an economic and affordable alternative. There are several species used to treat different disease such as Annona muricate, commonly know as Guanabana that is used for different diseases as anticonvulsant, antiparasitic, antimalarial, hepatoprotective, antidiabetic, etc. It has been reported that various parts of the plant have antiproliferative activity in diferent cancer cells lines, so in this work the objective was to study the anticancer activity of Annona muricate skin in vitro in A549 cell lines of lung cancer. An ethanolic crude extract was prepared from the Guanabana skin. The crude extract was subjected to preliminary chemical tests, to know the chemical content of the extract and was subjected to several chromatographic techniques using different stationary and mobile phases. Biological tests were carry out using lung cancer cells A549usin Paclitaxel as a positive control. From the ethanolic extract was isolated a flavonoid that was identified by nuclear magnetic resonance as 2-(4´hydroxyphenil)-5,7—dihydroxy-chromone. The results of the activity. The results of the activity on the viability of the lung cells cancer showed that a 300 µg/mL induces a cytotocyc action in the A549 cell line presenting a similar effect to the drug Paclitaxel which is a broad spectrum anticancer compound.

    Time:
    15:50-16:15

    Title: Psychological Risk Factors for Cancer?

    Shulamith Kreitler
    Tel- Aviv University and Psychooncology Research Center, Sheba Medical Center, Israel

    Biography
    χ

    Biography

    Shulamith Kreitler
    Tel- Aviv University and Psychooncology Research Center, Sheba Medical Center, Israel

    Shulamith Kreitler is a full professor of psychology at Tel Aviv University since 1986, and has worked at Princeton, Harvard and Yale Universities. She is a certified clinical psychologist and health psychologist. She has established (in 1993) the unit of psychooncology at the Tel Aviv Medical Center and (in 2007) the Center for Psychooncology Research at the Sheba Medical Center, Tel-Hashomer and functions as its director. Her major publications are in cognition, personality, and psychooncology. She has developed a new approach to meaning, and for predicting and changing psychological risk factors for chronic diseases.



    Abstract
    χ

    Abstract

    Shulamith Kreitler
    Tel- Aviv University and Psychooncology Research Center, Sheba Medical Center, Israel

    The talk will present a theoretical and methodological approach to defining the nature and role of psychological factors as risk factors for cancer diseases. The approach assumes that psychological risk factors are one kind of risk factors functioning in the presence of other kinds of risk factors affecting the chances for the occurrence and course of disease in the presence of a pathogen which is of a physical nature. A psychological methodology based on the cognitive orientation theory will be described for identifying relevant psychological risk factors for diseases and validating them. These factors are beliefs of four kinds (about oneself, about others and reality, about rules and norms, and about goals and wishes) referring to particular individually-shaped meanings. Two studies will be presented, one describing the cognitive orientation cluster characteristic of breast cancer, the other describing the impact of a cognitive orientation cluster on the duration of disease-free interval in three cancer diagnoses.

    Time:
    16:15-16:40

    Title: Cancer Metastasis and Interctions with Bone Micoenvironment

    Razi Vago
    Ben Gurion University of the Negev, Israel

    Biography
    χ

    Biography

    Razi Vago
    Ben Gurion University of the Negev, Israel

    Prof. Vago earned his Ph.D. from the Department of Life Science, Bar-Ilan University. He was later gained an Australian Institute of Marine Science Post Doctoral Fellow award. In 2000 he took a part in the foundation of the Department Biotechnology Engineering at Ben-Gurion University. He is a recipient of the Koret Foundation Grant Award for 1998 and 1999, and the Israeli Ministry of Science Grant Award and fellowship (1999-2000). In last six years Prof. Vago is the Head of the Avram and Stella Goldstain-Goren Department of Biotechnology Engineering. The research in his laboratory combines bioengineering and basic approaches for studying biology and bioengineering of mesenchymal stem cells on one hand and their role in development and metastasis of cancer on the other.



    Abstract
    χ

    Abstract

    Razi Vago
    Ben Gurion University of the Negev, Israel

    Solid cancers originating in the breast, prostate, and lung tend to metastasize to bone. Once deployed in bone these tumor cells harness this microenvironment, shift to a quiescent mode or initiate a vicious cycle that often leads bone destruction and gain an increased tumorigenicity by mechanisms which are not yet fully understood. Here we introduce a new three-dimensional model which closely resembles a living natural bone that can be used to study cellular and molecular cues in bone tumors and metastasis. Using this model we showed that the mineral phase may have an important role on cellular characteristics of mesenchymal stem cells (MSC's) and toumor cells. We also revealed that interactions with MSC's increased migration and invasion capacities along with fibrosarcomas (FS) and osteosarcomas (OS) proliferation. Moreover, we showed that via regulation of pathways such Wnt, cadherins, Notch and their downstream target genes such as c-Myc, these capacities were further enhanced when accommodated with the bone like biolattice and directly interacted with the MSCs. We also suggest that progression in OS aggressiveness can also can be attributed to a transition in Wnt signaling from canonical to noncanonical pathways, which is intensified in presence of MSCs. We suggest these kind of tumor promoting interactions may be found in the natural and tumorigenic bone microenvironment. New insights on the interplay between these signaling cues and their effects tumor progression will be discussed. A better understanding of the molecular signaling mechanisms involved in the tumor development and bone metastasis may contribute to development of new cancer therapies.

    Time:

    Title: Psycho-Social Care for Family Members of Patients with Metastatic Cancer

    Miri Cohen
    University of Haifa, Israel

    Biography
    χ

    Biography

    Miri Cohen
    University of Haifa, Israel



    Abstract
    χ

    Abstract

    Miri Cohen
    University of Haifa, Israel

    Objective: To assess the effect of cognitive – behavior group intervention on the psychological distress and adjustment of relatives of cancer patients with advanced disease. Methods: 41 caregivers of cancer patients with advanced disease participated in the intervention group and 33 served as controls. Participants completed pre- and post-intervention, and a 4-month follow-up questionnaire consisting of the Brief Symptom Inventory (BSI), Psychological Adjustment to Illness scale (PAIS), Mini sleep questionnaire (MSQ), Fatigue Symptoms Inventory (FSI) and Multidimensional Scale of Perceived Social Support (MSPSS). Participants also reported adherence to home practice. Results: While the two groups were similar on T1 in all study variables, at T2 the intervention group scored significantly lower than the control subjects on the BSI and the PAIS and recorded fewer sleep difficulties. The positive changes were preserved on T3 measure for the intervention group, while conditions of the control group worsened. Improvement in the intervention group was associated with higher compliance with home practice and with increase in perceived social support. Conclusion: This study provides evidence for the positive effect of a cognitive-behavior group intervention on the family members of cancer patients with metastatic disease; the effect lasted for 4 months after the intervention ended.

  • Sessions:
    Poster Presentations

    Time:

    Title: The State of Oncological Care and Ways of Improvement with Malignant Neoplasms in the Republic of North Ossetia-Alania in 1990-2014

    Alana Bosieva
    P.A. Hertsen Moscow Oncology Research Center, Russia

    Biography
    χ

    Biography

    Alana Bosieva
    P.A. Hertsen Moscow Oncology Research Center, Russia



    Abstract
    χ

    Abstract

    Alana Bosieva
    P.A. Hertsen Moscow Oncology Research Center, Russia

    Purpose of the study. Analysis of the state of cancer care and ways to improve it in malignant tumors in the Republic of North Ossetia-Alania (RNO-Alania). Materials and methods. Forms No. 7, No. 35, No. 5 (Table No. C51), Table 2 PH. Results. The main indicators of oncological care for 43596 patients with malignant neoplasms were analyzed. Active detection of patients averaged 8.6%. At averaged 5-year intervals, it corresponded to: 1990-1994. - 6.7%, 1995-1999. - 7.6%, 2005-2009. - 9.4%, 2000-2004 - 10.1%, 2010-2014. - 9.0%, i.e. Has grown in 1,3 times. The diagnosis was verified morphologically in 82.7%. In the last 5-year period (80.1%) compared with the first (75.2%), an improvement of 1.06 times. In the early (I-II) stage, the disease was detected in 52.1%. In the last 5-year period (55.0%) compared with the first (50.6%), an improvement of 1.09 times. In the third stage, on average, 24.0%, in the last and first 5-year period 22.7% and 21.6%. In the IV stage, 23.8%, 22.2% and 23.8%, respectively. There is no improvement in these indicators. The contingent of patients on the register is 1349.6 per 100 000 population. In the last 5-year period (1913.3) compared with the first (949.2) increased by 2 times. However, an average of 51.8% is recorded on the account for 5 years and more, and the indicator of 5-year survival of the last period (52.9%) has not changed compared to the first (52.3%). That is, the growth of this indicator due to the increase in morbidity. In the first year after the diagnosis was established, 26.2% died. In the last 5-year period (24.2%) in comparison with the first (30.6%) decrease in 1.3 times. One-year mortality rate is 41.3%. The indicator of the last 5-year period (43.5%) compared to the first (42.7%) did not change. The number of patients who completed special treatment is 51.4%. The indicator of the last 5-year period (61.7%) compared to the first (44.2%) increased by 1.4 times. Of these, only surgical treatment is 18.6%. The indicator of the last 5-year period (20.4%) compared to the first (16.1%) increased by 1.3 times. Combined or complex treatment received 18.1%. In the last 5-year period (24.9%) compared to the first (12.8%), it increased 1.9 times. Chemoradiation treatment - 0,9%, only medicinal - 2,6%. Conclusion. The indicators of active detectability and early detection of patients are low. Loss and mortality are high. A low percentage of surgical treatment and a survival rate of 5 years or more. The introduction of screening programs for cancer, increasing the oncological alertness of doctors of the treatment network and medical literacy of the population are mandatory.

    Time:

    Title: Progesterone through Progesterone Receptor-B Inhibits Invasion of Human Breast Cancer Cells by Targeting Cytoplasmic Cyclin D1

    Francesca De Amicis
    University of Calabria, Italy

    Biography
    χ

    Biography

    Francesca De Amicis
    University of Calabria, Italy

    Francesca De Amicis is an Assistant Professor of Applied Biology, Faculty of Pharmacy and Science of Nutrition and of Health at University of Calabria, Italy. In 1992 he did his Ph.D in Experimental Oncology, Italy. From 2005-2006 he was an Postdoctoral Associate at Breast Center, Baylor College of Medicine, Houston-Texas, USA. His Research Interests include Role of Steroid receptors in tumorogenesis of hormone-dependent tissues.



    Abstract
    χ

    Abstract

    Francesca De Amicis
    University of Calabria, Italy

    Introduction: Progesterone Receptor (PR) positivity is associated with a good prognosis and better response to breast cancer treatment. Conversely, cyclin D1 (CD1) is retained a marker of poor outcome since it has been associated with breast cancer metastasis in clinical studies. Material and method: 17-Hydroxyprogesterone (OHPg) was from Sigma-Aldrich. Antibodies and Protein A/GPLUS-Agarose were from Santa Cruz Biotechnology. T47-D, MCF-7 and MDA-MB-231 human breast cancer cells from the American Type Culture Collection; Total real-time RT-PCR assay; Western blotting and immunoprecipitation; Transfections and luciferase assays; Lipid-Mediated Transfection of siRNA Duplexes; Chromatin immunoprecipitation (ChIP) assays and realtime ChIP; Wound-healing assays; Transmigration assays; Cell invasion assay; Phalloidin staining Results and Discussion: Herein we provide evidences that OHPg through PR-B isoform, reduces motility and invasion of T47-D and MCF-7 breast cancer cells, by targeting the cytoplasmic CD1. Specifically, OHPg reduces CD1 expression through a transcriptional mechanism due to the occupancy of CD1 promoter at a canonical half progesterone responsive element by PR-B. This allows the recruitment of HDAC1 influencing a less permissive chromatin conformation for gene transcription and release of RNA Pol II. CD1 has an active role in the control of cell migration and metastasis through the interaction with key components of focal adhesion such as Paxillin (Pxn). In untreated T47-D and MCF-7 cells a specific co-immunoprecipitation of endogenous cytoplasmic CD1 with Pxn was observed. In untreated T47-D and MCF-7 cells a specific co-immunoprecipitation of endogenous cytoplasmic CD1 with Pxn was detected. Interestingly, OHPg exposure reduced the interaction between these proteins although total Pxn expression was substantially unaffected. Moreover a concomitant reduction of p-Pxn levels was observed and these effects were required for OHPg/PR-B dependent delay in cell invasion, as evidenced by assays carried out with the phoshomimetic mutants of Pxn. Conclusions: Collectively these findings support the importance of PR-B expression in breast cancer cells behavior, suggesting potentiating of PR-B signaling as a prospective useful strategy to restrict breast tumour cells invasion and metastasis.

    Time:

    Title: Phototoxic Activity of New Chlorin Derivatives with Potential for Treatment against Tumor Cells

    Janice Rodrigues Perussi
    University of São Paulo, Brazil

    Biography
    χ

    Biography

    Janice Rodrigues Perussi
    University of São Paulo, Brazil



    Abstract
    χ

    Abstract

    Janice Rodrigues Perussi
    University of São Paulo, Brazil

    Photodynamic therapy (PDT) is based on the induction of diseased tissue damage by the combination of three components: a photosensitizer (PS), light of adequated wavelength to the PS, and molecular oxygen leading the cells to produce reactive oxygen species (ROS) and in consequence, apoptotic or necrotic death of the tumor. In this study two new chlorins with L-type shape structure were synthesized from protoporphyrin IX dimethyl ester and 1-(3-phenylpropyl)-1H-pyrrole-2,5-dione by the Diels-Alder reaction aiming to avoid self-aggregation of the chlorins in physiological medium as well as to study the photodynamic action on HEp-2 tumor cells and Vero non-tumor cells. The chlorins CHL-Ph-A e CHL-Ph-B were characterized by 1H-NMR, 13C-NMR, UV-Vis and high resolution mass spectroscopy (HRMS). Their photochemical properties were determined such as quantum yield of singlet oxygen with a value around f0 = 0.69 and fluorescence quantum yield (ff = 0.0148) along with their photodegradation. The partition coefficient (Log P) of the CHL-Ph-A is 1.44 ± 0.06 and 1.42 ± 0.03 for the CHL-Ph-B showing an important amphiphilic character. The synthesized chlorins have a strong emission in 670 nm in DMSO (ԑ = ~2.20 x 104 M-1 cm-1), very low photobleaching, no aggregation, and a good phototoxicity leading to cell death by an apoptotic process in tumor cells as observed by fluorescence microscopy. The IC50 of the chlorins in tumor cells are as low as 65 nM for HEp-2 cells and they exhibited no cytotoxicity in non-tumour cells, demonstring selectivity. The results suggest that these chlorins derivatives are potential candidates to photosensitizers for PDT of cancer.

    Time:

    Title: Malignant neoplasms: Morbidity and Mortality in the Republic of North Ossetia-Alania in 1990-2014

    Alana Bosieva
    P.A. Hertsen Moscow Oncology Research Center, Russia

    Biography
    χ

    Biography

    Alana Bosieva
    P.A. Hertsen Moscow Oncology Research Center, Russia



    Abstract
    χ

    Abstract

    Alana Bosieva
    P.A. Hertsen Moscow Oncology Research Center, Russia

    Purpose of the study. Study of the dynamics of morbidity and mortality from malignant neoplasms in the Republic of North Ossetia-Alania (RNO-Alania). Materials and methods. Forms No. 7, No. 35, No. 5 (Table No. C51), Table 2 PH. Results. For 25 years in the Republican Oncology Dispensary, 45,498 patients were on treatment. Men - 20720 (45.5%), women - 24778 (54.5%). The average age of patients was 63.2 (63.1 for men, 63.4 for women). Up to 14 years of the male sex - 0.9%, 15-29 years - 1.7%, 30-44 years - 5.8%, 45-59 years - 24.8%, 60-74 years - 47.9% And ≥75 years - 18.9%. In the able-bodied age - 44.5% and pension - 56.4%. Up to 14 years of the female sex - 0.6%, 15-29 years - 1.8%, 30-44 years - 5.8%, 45-59 years - 25.2%, 60-74 years - 40.7% And ≥75 years - 23.1%. In working age - 25.4% and pension - 74.0%. The sex of children under the age of 14 is 0.7%, 15-29 is 1.7%, 30-44 is 7.4%, 45-59 is 25.0%, 60-74 is 44.0% And ≥75 years - 21.2%. The standardized indicator (world standard) of incidence for the entire follow-up period averaged 165.9 (men - 201.1 and women - 160.7) per 100 000 population. The averaged 5-year figures were in 1990-1994. - 142.9 (men - 167.4, women - 129.4); 1995-1999 - 158.4 (men - 184.4, women - 145.9); 2000-2004 - 168.3 (men - 194.5, women - 156.1); 2005-2009 - 187.9 (men - 212.5, women - 178.1); 2010-2014 - 207.7 (men - 246.6, women - 193.9) per 100 000 population. The number of deaths was 27403. Men - 45.1% and women - 54.9%. The average age of the deceased was 59.1 (men 59.2, women 58.6). Up to 14 years of the male sex - 1.5%, 15-29 years - 2.8%, 30-44 years - 9.3%, 45-59 years - 34.2%, 60-74 years - 38.0% And ≥75 years - 14.1%. Up to 14 years of the female sex - 1.0%, 15-29 years - 2.8%, 30-44 years - 13.8%, 45-59 years - 34.3%, 60-74 years - 34.5% And ≥75 years - 13.6%. In working age - 37.8% and pension - 61.2%. For both sexes, up to 14 years of age - 1.2%, 15-29 years - 2.8%, 30-44 years - 11.8%, 45-59 years - 34.2%, 60-74 years - 36.1% And ≥75 years - 13.9%. The standardized death rate averages 124.4 (men - 135.4 and women - 121.6) per 100 000 population. Averaged five-year mortality rates in 1990-1994. - 128.3 (men - 145.1, women - 121.1); 1995-1999 - 119.9 (men - 131.8, women - 115.3); 2000-2004 - 125.4 (men - 136.7, women - 121.2); 2005-2009 - 122.7 (men - 133.8, women - 120.9); 2010-2014 - 128.2 (men - 125.6, women - 129.5) per 100 000 population. Mortality does not tend to decrease. Conclusion. Morbidity of malignant neoplasms is growing. Mortality does not decrease.

    Time:

    Title: Cancer of the Stomach: The Dynamics of Morbidity, Mortality and the State of Cancer Care in the Republic of North Ossetia-Alania in 1993-2012

    Alana Bosieva
    P.A. Hertsen Moscow Oncology Research Center, Russia

    Biography
    χ

    Biography

    Alana Bosieva
    P.A. Hertsen Moscow Oncology Research Center, Russia



    Abstract
    χ

    Abstract

    Alana Bosieva
    P.A. Hertsen Moscow Oncology Research Center, Russia

    Stomach cancer (RJ) remains an urgent health problem. Purpose of the study. Analysis of the state of oncological care for breast cancer and ways of improvment in the Republic of North Ossetia-Alania (RNO-Alania). Materials and methods. Forms No. 7, 35, 5 (Table C51), Table 2 PH, the history of diseases of the deceased. Results. For 20 years on treatment there were 2499 patients with RZ in the Republican Oncology Dispensary. Men - 1404 (56.2%) and women - 1095 (34.8%). The average age of patients was 65.1 (65.4 m, 66.2 w.). The standardized indicator (world standard) of the incidence, in general, was 12.1 (m. - 17.8 and w-8.5) per 100 000 population. The incidence of men is 2.1 times greater than that of women. The averaged five-year figures for both sexes in 1993-1997. - 14.5; 1998-2002 - 12.2; 2003-2007 - 11.4; 2008-2012 - 10.4. The indicator of the last 5-year period compared with the first decreased by 1.4 times. In men, these indicators: 21.0, 17.5, 17.1 and 15.5 respectively. Decrease in 1,4 times. In women: 10.3, 8.7, 7.8 and 7.1 decrease by 1.5 times. The overall rate of decline is 37.5 (m. - 33.5 and w.41.7). The average annual rate of decline is 1.9 (m - 1.7 and w. - 2.2). Died 2204 patients from RZ. M. - 1210 (54.9%) and w. - 994 (45.1%). The average age of the deceased is 66.7 (66.2 m, 66.8 w.). The standardized mortality rate in general is 8.1 (m - 10.9 and w. - 5.7) per 100 000 population. Mortality y is 1.9 times greater than that of women. The averaged five-year figures for both sexes in 1993-1997. - 8.7; 1998-2002 - 8.1; 2003-2007 - 7.6; 2008-2012 6.9. The last 5-year indicator in comparison with the first decreased by 1.2 times. In men, these indicators: 13.8, 11.6, 11.4 and 10.3 respectively. Decrease in 1,3 times. In women: 6,8, 5,8, 5,2 and 4,7 decrease in 1,4 times. The rate of decrease is 28.8 (m - 26.4 and w - 31.8). The average annual rate of decline is 1.8 (m - 1.9 and w. - 2.0). Active detection of RJ on average 1.1%. Morphological verification of the diagnosis 72,4%. Detection of RJ in the I-II stage was 20.8% on average, III - 36.0% and IV stage - 43.2%. The prevalence of RD is 38.6 per 100 000 population on average. Survival of patients 5 years or more on average 42.5%. In the last 5 years compared with the first increased 1.2 times. On average, only 28.2% of patients received special treatment. Surgical 77.4% and combined 22.1%. In the last 5 years, 56.6% of surgical treatment was received, which is 1.5 times lower compared to the first (86.8%), and combined, respectively 43.3 and 13.2, increased 3.3 times. Mortality in the 1st year is on the average 50.6%. The indicator of the last 5-year period compared with the first decreased by 1.2 times. Conclusion. Incidence of RJ for the observed period decreased. The active detection and detection of RY I-II stages are low, the percentage of neglect is high. Mortality remains high. Survival is 5 years and lower. It is necessary to increase the literacy of the population, carry out endoscopic screening programs of the population at risk for RJ and precancerous gastroduodenal diseases, and their timely treatment.

    Time:

    Title: The Survey of Environmental Etiology about the Epidemic of Rampant Cancers in Tehran City by Geographical Information System

    Bahador Ighanian
    Iran

    Biography
    χ

    Biography

    Bahador Ighanian
    Iran



    Abstract
    χ

    Abstract

    Bahador Ighanian
    Iran

    Geographical Information System is a computerized system for managing and analyzing the geographic information. It has the capability to gather, save, analyze and show the geographic information. Considering utilizing of zip codes has segregation of information in residential usage, the experts of the ministry of health and medical support this method (utilizing zip codes) as the best way to reach to their aims. Digitizing 18 sheets of the plans of Tehran considering various methods of clarification of existent information including 700 thousand informational records, were analyzed and tested by different softwares like ArcGIS, Arcview, Edvisi, Ilwis and AutoCAD. These methods contain, rechecking the information by operators and clarification of information on the postal and geographical plans by mentioned soft –wares. As the addresses in the files of The Office of Codifying were edited in three parts (sector, penultimate pass way, last pass way ) The program firstly verifies all three fields with data bank of cancer to attribute 5 digits codes to patient's address, and then if two fields in one record are verified with data bank , 5 digits of zip code is attributed to the patient's address and finally all records which have received codes are eliminated thus these records are moved out of the comparing circle. The plans show that the most aggregated zone of cancer epidemic is Bazar and south west is the second most aggregated zone. This method can be use in several cases such as EOC GIS (Emergency Operation Center), Sustainable development, health GIS, Crime GIS, Educational management, Economical cases and any other macro managements system.

Tags

  • Submit Abstract Register Guidelines Program Brochure
  • Join our Mailing List


    © Copyrights 2017. www.madridge.org, CC-By This work is licensed under a Creative Commons Attribution 4.0 International License.